Current Report Filing (8-k)
June 26 2018 - 5:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 20, 2018
SUNESIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-51531
|
|
94-3295878
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
395 Oyster Point Boulevard, Suite 400
South San Francisco, California
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650)
266-3500
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
As previously disclosed on a current report on Form
8-K,
Sunesis Pharmaceuticals, Inc. (the Company) appointed Dayton Misfeldt as its interim Chief Executive Officer, effective January 1, 2018, and, as consideration for his services in such
interim role through June 30, 2018, Mr. Misfeldt was granted an option to purchase 200,000 shares of the Companys common stock pursuant to its 2011 Equity Incentive Plan (the Plan), to vest in six equal monthly
installments measured from January 1, 2018. Since the Company expects Mr. Misfeldt to continue in the interim Chief Executive Officer role as the Company continues its search for a permanent Chief Executive Officer and, as compensation for
his continued service in this role, on June 20, 2018, the Company granted Mr. Misfeldt an additional option to purchase 200,000 shares of the Companys Common Stock, pursuant to the Plan, with an effective grant date of June 29,
2018, (the last business day of the month, in accordance with the Companys practice), to vest monthly over six equal monthly installments measured from the grant date. All rights and obligations with respect to Mr. Misfeldts new
grant will be as set forth in the Plan and applicable Plan documents.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SUNESIS PHARMACEUTICALS, INC.
|
|
|
|
|
Dated: June 26, 2018
|
|
|
|
By:
|
|
/s/ William P. Quinn
|
|
|
|
|
|
|
William P. Quinn
|
|
|
|
|
|
|
Chief Financial Officer, Senior Vice President, Finance and Corporate Development
|
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024